Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Orphan Drug Pricing Heading To Negotiating Table in US?

Executive Summary

The Institute for Clinical and Economic Review is launching an initiative to adapt its value assessment approach to orphan and ultra-orphan drugs, including a possible consideration of what should be a fair return on investment for manufacturers.

You may also be interested in...



Orphan Drug Policy Changes To Be Considered Under US FDA's FY 2019 Budget Proposal

Proposed $20m funding boost for rare disease development includes review of orphan incentives, including how to potentially stimulate development in ultra-orphan diseases.

US FDA Doesn't Support Creating Ultra-Orphan Designation

Agency is already approving drugs for diseases with much smaller patient populations than the traditional rare disease, officials note.

Orphan Incentives: Voucher Price Drop Gives Some Sponsors 'Pause'

Is the lower sale price making the opportunity for a priority review voucher less an incentive for orphan development?

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS120793

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel